BIIB Jan 2023 310.000 put
| Previous close | 98.48 |
| Open | 98.48 |
| Bid | 77.50 |
| Ask | 86.50 |
| Strike | 310.00 |
| Expiry date | 2023-01-20 |
| Day's range | 98.48 - 98.48 |
| Contract range | N/A |
| Volume | |
| Open interest | 64 |
- Zacks
Ionis' (IONS) Partner to Begin New Huntington's Disease Study
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.
- Motley Fool
Is Biogen a Buy After the Latest Aduhelm Disaster?
Biogen's (NASDAQ: BIIB) stock is taking yet another body blow since the Centers for Medicare and Medicaid Services (CMS) issued a draft ruling on Jan. 12 that the company's troubled new Alzheimer's drug, Aduhelm, wouldn't be covered by the U.S. public insurance plans except in the context of patients enrolled in clinical trials. In my view, there isn't much hope for Aduhelm's fortunes to reverse anytime soon.
- Motley Fool
Where Will Biogen Be in 5 Years?
Biogen (NASDAQ: BIIB) investors recently received an unwelcome surprise from an important government agency. The phrase "coverage with evidence development" (CED) might not sound too serious, but these words from the Centers for Medicare & Medicaid Services (CMS) were heavy enough to put Biogen's stock price under pressure on Wednesday, Jan. 12, 2022. The CMS decision was tough on Biogen stock price in the short term, but what do the next five years have in store?
